China's dermatology has developed rapidly, and biologic therapy for psoriasis has entered a new era. With the approval of multiple biologics and oral small-molecule drugs targeting psoriasis, the treatment outcomes and quality of life of patients with moderate-to-severe psoriasis have undergone revolutionary improvement.
New breakthroughs in psoriasis treatment
Traditional treatments have limited efficacy and significant side effects for moderate-to-severe psoriasis. Biologics, by precisely targeting immune pathways, significantly improve skin clearance rates, and some patients can achieve near-complete clearance, with continuously improving long-term safety data. Oral small-molecule drugs (such as JAK inhibitors and PDE4 inhibitors) offer more options for patients who cannot easily use injections.
Treatment strategy and personalization
Modern psoriasis treatment emphasizes personalization and long-term management. Doctors comprehensively formulate treatment plans based on disease severity, comorbidities (such as psoriatic arthritis) and patient preferences.
Significance for international patients
For patients with moderate-to-severe psoriasis, standardized biologic treatment can significantly improve quality of life. The variety of biologics approved in China is rich, and treatment costs are more cost-effective compared with some countries.
MedBridge services
MedBridge can connect international patients with dermatology specialty hospitals in Shanghai, providing medical record evaluation, expert appointment, treatment plan consultation and long-term follow-up services.